The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer

Marina Frimer, June Y. Hou, Thomas C. McAndrew, Gary L. Goldberg, Shohreh Shahabi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The utility of cancer antigen 125 (CA-125) levels as an adjunct method of monitoring patients with uterine papillary serous carcinoma (UPSC) or endometrial serous carcinoma after surgery and adjuvant treatment has been reported. Our goal was to determine the significance of rising CA-125 levels within the normal range in these patients in the posttreatment surveillance setting. All patients with UPSC who underwent surgical staging and had preoperative CA-125 measurement from 1999 to 2008 were included in this analysis. Information was extracted from records to assess the changes in CA-125 values with clinical and/or radiographic detection of recurrence. Of the 56 evaluable patients, 23 (41%) recurred. Of the 23 patients that recurred, 11 had serial CA-125 levels measured in remission. Elevated CA-125 levels at diagnosis were significantly associated with disease recurrence and advanced stage (P =.01, P =.001, respectively). The rise in CA-125 by 10 U/mL in the normal range and ≥15 U/mL were associated with disease recurrence (P <.001, P <.001, respectively). In multivariate analysis, only CA-125 level ≥15 U/mL was significantly associated with worse progression-free survival. In this small cohort of patients with recurrent UPSC after remission, surveillance of CA-125 levels may have a role in disease surveillance and management.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalReproductive Sciences
Volume20
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Reference Values
Antigens
Neoplasms
Papillary Carcinoma
Recurrence
Physiologic Monitoring
Endometrial Neoplasms
Disease Management
Disease-Free Survival
Multivariate Analysis

Keywords

  • CA-125
  • endometrial cancer
  • tumor markers
  • uterine papillary serous carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer. / Frimer, Marina; Hou, June Y.; McAndrew, Thomas C.; Goldberg, Gary L.; Shahabi, Shohreh.

In: Reproductive Sciences, Vol. 20, No. 4, 04.2013, p. 449-455.

Research output: Contribution to journalArticle

Frimer, Marina ; Hou, June Y. ; McAndrew, Thomas C. ; Goldberg, Gary L. ; Shahabi, Shohreh. / The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer. In: Reproductive Sciences. 2013 ; Vol. 20, No. 4. pp. 449-455.
@article{d34d6e48d66141cb8b2479da3b1643c4,
title = "The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer",
abstract = "The utility of cancer antigen 125 (CA-125) levels as an adjunct method of monitoring patients with uterine papillary serous carcinoma (UPSC) or endometrial serous carcinoma after surgery and adjuvant treatment has been reported. Our goal was to determine the significance of rising CA-125 levels within the normal range in these patients in the posttreatment surveillance setting. All patients with UPSC who underwent surgical staging and had preoperative CA-125 measurement from 1999 to 2008 were included in this analysis. Information was extracted from records to assess the changes in CA-125 values with clinical and/or radiographic detection of recurrence. Of the 56 evaluable patients, 23 (41{\%}) recurred. Of the 23 patients that recurred, 11 had serial CA-125 levels measured in remission. Elevated CA-125 levels at diagnosis were significantly associated with disease recurrence and advanced stage (P =.01, P =.001, respectively). The rise in CA-125 by 10 U/mL in the normal range and ≥15 U/mL were associated with disease recurrence (P <.001, P <.001, respectively). In multivariate analysis, only CA-125 level ≥15 U/mL was significantly associated with worse progression-free survival. In this small cohort of patients with recurrent UPSC after remission, surveillance of CA-125 levels may have a role in disease surveillance and management.",
keywords = "CA-125, endometrial cancer, tumor markers, uterine papillary serous carcinoma",
author = "Marina Frimer and Hou, {June Y.} and McAndrew, {Thomas C.} and Goldberg, {Gary L.} and Shohreh Shahabi",
year = "2013",
month = "4",
doi = "10.1177/1933719112459218",
language = "English (US)",
volume = "20",
pages = "449--455",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer

AU - Frimer, Marina

AU - Hou, June Y.

AU - McAndrew, Thomas C.

AU - Goldberg, Gary L.

AU - Shahabi, Shohreh

PY - 2013/4

Y1 - 2013/4

N2 - The utility of cancer antigen 125 (CA-125) levels as an adjunct method of monitoring patients with uterine papillary serous carcinoma (UPSC) or endometrial serous carcinoma after surgery and adjuvant treatment has been reported. Our goal was to determine the significance of rising CA-125 levels within the normal range in these patients in the posttreatment surveillance setting. All patients with UPSC who underwent surgical staging and had preoperative CA-125 measurement from 1999 to 2008 were included in this analysis. Information was extracted from records to assess the changes in CA-125 values with clinical and/or radiographic detection of recurrence. Of the 56 evaluable patients, 23 (41%) recurred. Of the 23 patients that recurred, 11 had serial CA-125 levels measured in remission. Elevated CA-125 levels at diagnosis were significantly associated with disease recurrence and advanced stage (P =.01, P =.001, respectively). The rise in CA-125 by 10 U/mL in the normal range and ≥15 U/mL were associated with disease recurrence (P <.001, P <.001, respectively). In multivariate analysis, only CA-125 level ≥15 U/mL was significantly associated with worse progression-free survival. In this small cohort of patients with recurrent UPSC after remission, surveillance of CA-125 levels may have a role in disease surveillance and management.

AB - The utility of cancer antigen 125 (CA-125) levels as an adjunct method of monitoring patients with uterine papillary serous carcinoma (UPSC) or endometrial serous carcinoma after surgery and adjuvant treatment has been reported. Our goal was to determine the significance of rising CA-125 levels within the normal range in these patients in the posttreatment surveillance setting. All patients with UPSC who underwent surgical staging and had preoperative CA-125 measurement from 1999 to 2008 were included in this analysis. Information was extracted from records to assess the changes in CA-125 values with clinical and/or radiographic detection of recurrence. Of the 56 evaluable patients, 23 (41%) recurred. Of the 23 patients that recurred, 11 had serial CA-125 levels measured in remission. Elevated CA-125 levels at diagnosis were significantly associated with disease recurrence and advanced stage (P =.01, P =.001, respectively). The rise in CA-125 by 10 U/mL in the normal range and ≥15 U/mL were associated with disease recurrence (P <.001, P <.001, respectively). In multivariate analysis, only CA-125 level ≥15 U/mL was significantly associated with worse progression-free survival. In this small cohort of patients with recurrent UPSC after remission, surveillance of CA-125 levels may have a role in disease surveillance and management.

KW - CA-125

KW - endometrial cancer

KW - tumor markers

KW - uterine papillary serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84875695491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875695491&partnerID=8YFLogxK

U2 - 10.1177/1933719112459218

DO - 10.1177/1933719112459218

M3 - Article

VL - 20

SP - 449

EP - 455

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 4

ER -